ImmunityBio, Inc. - Common Stock (IBRX)

Competitors to ImmunityBio, Inc. - Common Stock (IBRX)

AstraZeneca plc

AstraZeneca is a global biopharmaceutical company known for its strengths in oncology and respiratory diseases. The company has made notable advancements in immune-oncology with its own range of therapies targeting various cancers. Its established reputation, large-scale production capabilities, and deep pipeline can leverage competitive advantages over ImmunityBio, which is still building its foothold in these areas. AstraZeneca's strong partnerships and collaborations further enhance its competitive positioning.

Bristol Myers Squibb Company 

Bristol Myers Squibb (BMS) is a major player in the oncology space, offering a diversified portfolio of immunotherapy products and strong research capabilities. Their extensive clinical trial infrastructure and established market presence for cancer treatments pose significant competition for ImmunityBio. BMS's leadership in immune checkpoint inhibitors provides it with a competitive advantage, as they have successfully brought multiple cancer therapies to market, while ImmunityBio is still in various stages of development.

Gilead Sciences, Inc. 

Gilead Sciences is recognized for its robust antiviral therapeutics but is also investing in oncology. Their portfolio includes a variety of cancer drugs that target specific pathways, offering fierce competition as ImmunityBio seeks to establish itself in the same domain. Gilead's extensive resources, history of successful drug development, and substantial market presence afford it a competitive advantage over newer entrants like ImmunityBio, which is still gaining traction.

Moderna, Inc. 

Moderna focuses primarily on mRNA technology for vaccine development, which positions it strongly in the rapidly evolving vaccine and therapeutic markets, especially in infectious diseases and cancer. Its substantial partnerships and collaborations, particularly in response to the COVID-19 pandemic, have allowed it to gain a significant market presence. While ImmunityBio also targets cancer and infectious diseases with its immunotherapy approaches, Moderna's established track record in mRNA technologies gives it a competitive edge in terms of research, funding, and regulatory approvals.

Novartis AG 

Novartis has a comprehensive portfolio in pharmaceuticals and biosimilars, with significant investments in oncology and immunotherapy. Their established drug offerings and significant R&D investments allow them to compete effectively with ImmunityBio in the immuno-oncology space. The scale and infrastructure of Novartis provide a structural advantage in terms of development, commercialization, and market reach compared to smaller companies like ImmunityBio, who are more focused on niche therapies.